La catena delle opzioni mostra i dati chiave delle opzioni azionarie di VolitionRX a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per VolitionRX..

VolitionRX (AMEX:VNRX) Azioni, Catena delle Opzioni

VolitionRX

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

VolitionRX Ltd

VolitionRX (VNRX) has provided an announcement. VolitionRx Limited has released its mid-year review, which is now accessible on the Investor Relati...

VolitionRX Mid-Year Review Update Now Available

An update from VolitionRX (VNRX) is now available. At the recent Annual Meeting, stockholders of the Company made key decisions affecting the futur...

VolitionRX Stockholders Set Course with Key Governance Decisions

VolitionRx prices its $21.5M direct offering

VolitionRX Q2 2024 Earnings Preview

Here's the major earnings before the open tomorrow

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>VolitionRX</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/vnrx-stock-quote/"><strong>VNRX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>VolitionRX reported earnings per share of -8 cents. This was above the analyst estimate for EPS of -9 cents.</li><li>The company reported revenue of $395,797.</li><li>This was 17.54% worse than the analyst estimate for revenue of $480,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/vnrx-stock-earnings-volitionrx-for-q2-of-2024/">VNRX Stock Earnings: VolitionRX Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

VNRX Stock Earnings: VolitionRX Beats EPS, Misses Revenue for Q2 2024

VolitionRX reports Q2 results

VolitionRx Limited (VNRX) Q2 2024 Earnings Call Transcript

Benchmark Co. analyst Bruce Jackson maintained a Hold rating on VolitionRX (VNRX – Research Report) today. The company's shares closed yesterday at...

Benchmark Co. Remains a Hold on VolitionRX (VNRX)

VolitionRX ( ($VNRX) ) has shared an announcement. Belgian Volition SRL has renewed its commitment to Dr. Gaetan Michel as CEO with a new employmen...

VolitionRX Confirms Dr. Michel's Leadership and Compensation Plan

ADYEY

BABA

BLRX

BPTH

CBWTF

GLNG

GRAB

GRYP

ITMPF

LFWD

LNVGY

LYTS

NICE

SPCB

SPTN

TRMD

VNRX

Press Releases

VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting

Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing

VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update

Offerings

VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering

VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update

Volition Hosts KOL Roundtable on Sepsis

Volition Appoints Dr. Ethel Rubin as an Independent Director

Volition hosts NETs in sepsis management symposium at ESICM Lives 2024

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

Small Cap

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

Comments

VolitionRX

VolitionRX (VNRX) Opzioni

VolitionRX (AMEX:VNRX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO